Vigonvita Life Sciences Co., Ltd. (SEHK: 2630)
Health Care · Pharmaceuticals · CN
HK$72.65
-3.13% today · +7.7% 1Y
Vigonvita Life Sciences Co., Ltd. (SEHK: 2630) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.55B and employs 315 people.
Over the last twelve months the share price has gained 7.7%, trading between 52.00 and 134.90.
Tweenvest scores Vigonvita Life Sciences Co., Ltd. across four factors: quality 31/100, value 49/100. Its strongest factor is value.
2630 price history
Key figures
- Market cap
- $1.55B
- Revenue (TTM)
- $31.98M
- P/E
- -31.36
- EPS
- -2.59
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$134.90
- 52-week low
- HK$52.00
- Avg volume (3M)
- —
- Shares outstanding
- 167.60M
- Employees
- 315
- Next earnings
- —
About Vigonvita Life Sciences Co., Ltd.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.
- ISIN
- CNE1000076N3
- Founded
- 2013
- Listed since
- Nov 6, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287 | $1.60B | CN¥18.79 | +0.54% |
| Braveheart Bio, Inc.NasdaqGM: BRVE | $1.59B | $19.49 | -0.66% |
| Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572 | $1.57B | CN¥4.12 | -0.48% |
| Fujian Haixi Pharmaceuticals Co., Ltd.SEHK: 2637 | $1.57B | HK$156.00 | -0.32% |
| Marksans Pharma LimitedNSEI: MARKSANS | $1.53B | Rs318.50 | -0.47% |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | $1.51B | CN¥43.40 | -5.28% |
| ANI Pharmaceuticals, Inc.NasdaqGM: ANIP | $1.51B | $71.47 | +2.11% |
| Xiamen Kingdomway Group CompanySZSE: 002626 | $1.51B | CN¥16.94 | +0.89% |